JP2001526269A5 - - Google Patents

Download PDF

Info

Publication number
JP2001526269A5
JP2001526269A5 JP2000525392A JP2000525392A JP2001526269A5 JP 2001526269 A5 JP2001526269 A5 JP 2001526269A5 JP 2000525392 A JP2000525392 A JP 2000525392A JP 2000525392 A JP2000525392 A JP 2000525392A JP 2001526269 A5 JP2001526269 A5 JP 2001526269A5
Authority
JP
Japan
Prior art keywords
substituted
group
alkyl
twenty
perhalo substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000525392A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001526269A (ja
JP4395823B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/026082 external-priority patent/WO1999032455A1/en
Publication of JP2001526269A publication Critical patent/JP2001526269A/ja
Publication of JP2001526269A5 publication Critical patent/JP2001526269A5/ja
Application granted granted Critical
Publication of JP4395823B2 publication Critical patent/JP4395823B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000525392A 1997-12-22 1998-12-22 アリール及びヘテロアリール置換複素環式尿素を用いたrafキナーゼの阻害 Expired - Fee Related JP4395823B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99618197A 1997-12-22 1997-12-22
US08/996,181 1997-12-22
PCT/US1998/026082 WO1999032455A1 (en) 1997-12-22 1998-12-22 Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas

Publications (3)

Publication Number Publication Date
JP2001526269A JP2001526269A (ja) 2001-12-18
JP2001526269A5 true JP2001526269A5 (cg-RX-API-DMAC7.html) 2006-01-05
JP4395823B2 JP4395823B2 (ja) 2010-01-13

Family

ID=25542594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000525392A Expired - Fee Related JP4395823B2 (ja) 1997-12-22 1998-12-22 アリール及びヘテロアリール置換複素環式尿素を用いたrafキナーゼの阻害

Country Status (28)

Country Link
EP (1) EP1056725B1 (cg-RX-API-DMAC7.html)
JP (1) JP4395823B2 (cg-RX-API-DMAC7.html)
KR (1) KR100622138B1 (cg-RX-API-DMAC7.html)
CN (1) CN1117081C (cg-RX-API-DMAC7.html)
AT (1) ATE328873T1 (cg-RX-API-DMAC7.html)
AU (1) AU765412B2 (cg-RX-API-DMAC7.html)
BG (1) BG65207B1 (cg-RX-API-DMAC7.html)
BR (1) BR9814361A (cg-RX-API-DMAC7.html)
CA (1) CA2315713C (cg-RX-API-DMAC7.html)
CU (1) CU23127A3 (cg-RX-API-DMAC7.html)
CY (1) CY1105395T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ299836B6 (cg-RX-API-DMAC7.html)
DE (2) DE69834842T2 (cg-RX-API-DMAC7.html)
DK (1) DK1056725T3 (cg-RX-API-DMAC7.html)
ES (1) ES2155045T3 (cg-RX-API-DMAC7.html)
GR (1) GR20010300010T1 (cg-RX-API-DMAC7.html)
HU (1) HUP0004426A3 (cg-RX-API-DMAC7.html)
ID (1) ID26328A (cg-RX-API-DMAC7.html)
IL (2) IL136773A0 (cg-RX-API-DMAC7.html)
NO (1) NO319209B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ505845A (cg-RX-API-DMAC7.html)
PL (1) PL341356A1 (cg-RX-API-DMAC7.html)
PT (1) PT1056725E (cg-RX-API-DMAC7.html)
RU (1) RU2265597C2 (cg-RX-API-DMAC7.html)
SK (1) SK285371B6 (cg-RX-API-DMAC7.html)
TR (3) TR200100918T2 (cg-RX-API-DMAC7.html)
UA (1) UA67763C2 (cg-RX-API-DMAC7.html)
WO (1) WO1999032455A1 (cg-RX-API-DMAC7.html)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1473292A1 (en) * 1997-11-03 2004-11-03 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
JP4437270B2 (ja) * 1997-12-22 2010-03-24 バイエル コーポレイション 置換複素環式尿素を用いたrafキナーゼの阻害
AU2006201959B2 (en) * 1997-12-22 2008-09-04 Bayer Healthcare Llc Inhibition of Raf Kinase using Substituted Heterocyclic Ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
IL136768A0 (en) * 1997-12-22 2001-06-14 Bayer Ag INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
CA2315720A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation Inhibition of p38 kinase activity using substituted heterocyclic ureas
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
MXPA01008440A (es) 1999-02-22 2002-04-24 Boehringer Ingelheim Pharma Derivados heterociclicos policiclos como agentes anti-inflamatorios..
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
TR200102817T2 (tr) 1999-03-12 2002-05-21 Boehringer Ingelheim Pharmaceuticals, Inc. Antiinflamatuar ajanlar olarak faydalı bileşikler
WO2000055152A1 (en) 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
CA2374737C (en) 1999-07-09 2008-02-12 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds
MXPA02001498A (es) * 1999-08-12 2003-07-21 Pharmacia & Italia S P A Derivados de 3(5)-amino-pirazol, procedimiento para la preparacion de los mismos y usos como agentes antitumorales.
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
CA2395564A1 (en) 1999-11-22 2001-05-31 Smithkline Beecham Plc Novel compounds
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
CA2416527C (en) * 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US7238813B2 (en) 2000-11-29 2007-07-03 Smithkline Beecham Corporation Chemical compounds
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
JP2004530690A (ja) 2001-05-16 2004-10-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症性薬剤として有用なジアリールウレア誘導体
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
MXPA03010724A (es) 2001-05-25 2004-03-02 Boehringer Ingelheim Pharma Compuestos de carbamato y oxamida como inhibidores de la produccion de citocina.
EP1709965A3 (en) * 2001-07-11 2006-12-27 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediate diseases
US7375105B2 (en) 2001-09-05 2008-05-20 Smithkline Beecham P.L.C. Pyridine substituted furan derivatives as Raf kinase inhibitors
EP2305255B1 (en) * 2001-12-03 2012-08-22 Bayer HealthCare LLC Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
WO2003068223A1 (en) * 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
ATE529406T1 (de) 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
EP1480973B1 (en) 2002-02-25 2008-02-13 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
MXPA05000945A (es) * 2002-07-25 2005-05-16 Pharmacia Italia Spa Biciclo-pirazoles activos como inhibidores de la cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
CA2516931C (en) 2003-02-28 2014-09-09 Bayer Pharmaceuticals Corporation Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
CA2526285A1 (en) 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
WO2005048953A2 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US7741490B2 (en) * 2004-03-19 2010-06-22 Dipharma S.P.A. Intermediates for the preparation of pramipexole
US7838524B2 (en) 2004-04-30 2010-11-23 Bayer Healthcare Llc Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2006010082A1 (en) 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
CA2584368A1 (en) 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
CA2592118C (en) 2004-12-23 2015-11-17 Deciphera Pharmaceuticals, Llc Urea derivatives as enzyme modulators
GB0500435D0 (en) * 2005-01-10 2005-02-16 Novartis Ag Organic compounds
DE602006017188D1 (de) 2005-03-07 2010-11-11 Bayer Schering Pharma Ag Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
WO2007018137A1 (ja) 2005-08-05 2007-02-15 Chugai Seiyaku Kabushiki Kaisha マルチキナーゼ阻害剤
DE102005037499A1 (de) 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
EP1960394A2 (en) * 2005-11-15 2008-08-27 Bayer HealthCare AG Pyrazolyl urea derivatives useful in the treatment of cancer
ES2480440T3 (es) * 2005-12-21 2014-07-28 Bayer Intellectual Property Gmbh Derivados sustituidos de pirimidina útiles en el tratamiento del cáncer y de otros trastornos
US20080045589A1 (en) 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
WO2008079972A2 (en) 2006-12-20 2008-07-03 Bayer Healthcare Llc 4-{4- [ ({3-tert-butyl-1- [3- (hydroxymethyl) phenyl] - 1h- pyrazol- 5 -yl } carbamoyl) -amin o] -3-chlorophenoxy} -n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancer
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008123963A1 (en) 2007-04-02 2008-10-16 Renovis, Inc. Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
WO2008140895A1 (en) 2007-04-20 2008-11-20 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
WO2009111278A2 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
AR072657A1 (es) 2008-02-29 2010-09-15 Genentech Inc Compuestos inhibidores de raf y metodos para su uso
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
BRPI0920707A2 (pt) 2008-10-02 2015-12-29 Respivert Ltd compostos
MX2011006219A (es) 2008-12-11 2011-06-28 Respivert Ltd Inhibidores de la proteina cinasa activada por el mitogeno p38.
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
JP5787976B2 (ja) 2010-04-08 2015-09-30 レスピバート・リミテツド P38mapキナーゼ阻害剤としてのピラゾリルウレア
EP2594566A4 (en) 2010-07-16 2014-10-01 Kyowa Hakko Kirin Co Ltd AROMATIC HETEROCYCLIC NITROGEN CYCLE DERIVATIVE
JP2013531067A (ja) 2010-07-19 2013-08-01 バイエル ヘルスケア リミティド ライアビリティ カンパニー 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
PL2763984T3 (pl) 2011-10-03 2016-10-31 1-pirazolilo-3-(4-((2-anilinopirymidyno-4-ilo)oksy)naftaleno-1-ilo)moczniki jako inhibitory kinazy p38 MAP
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
KR20140011780A (ko) * 2012-07-19 2014-01-29 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
EP2970190A1 (en) 2013-03-14 2016-01-20 Respivert Limited Kinase inhibitors
US9750723B2 (en) 2013-10-31 2017-09-05 Ohio University Prevention and treatment of non-alcoholic fatty liver disease
ES2774249T3 (es) 2014-02-14 2020-07-20 Respivert Ltd Compuestos heterocíclicos aromáticos como compuestos antiinflamatorios
WO2016010610A2 (en) 2014-07-18 2016-01-21 Ohio University Imidazole and thiazole compositions for modifying biological signaling
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
CR20200464A (es) 2018-03-08 2021-04-14 Incyte Corp Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
CN108484587A (zh) * 2018-06-03 2018-09-04 刘思良 一种Raf激酶抑制剂及其在癌症治疗中的应用
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
CN112823151B (zh) * 2018-07-03 2024-11-15 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
IL330104A (en) 2019-03-11 2026-08-01 Deciphera Pharmaceuticals Llc Crystalline forms of rifatinib
HRP20260411T1 (hr) 2019-08-12 2026-05-08 Deciphera Pharmaceuticals, Llc Ripretinib za liječenje gastrointestinalnih stromalnih tumora
US12691108B2 (en) 2019-08-12 2026-07-28 Deciphera Pharmaceuticals, Llc Methods for treating vascular malformations
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994455A (en) * 1987-10-26 1991-02-19 Pfizer Inc. Anti-anxiety agents
US5162360A (en) * 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
GB9302275D0 (en) * 1993-02-05 1993-03-24 Smithkline Beecham Plc Novel compounds
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
GB9623833D0 (en) * 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
AU7585598A (en) * 1997-05-23 1998-12-11 Bayer Corporation Raf kinase inhibitors
AU1367599A (en) * 1997-11-03 1999-05-24 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
IL136768A0 (en) * 1997-12-22 2001-06-14 Bayer Ag INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS

Similar Documents

Publication Publication Date Title
RU2000120162A (ru) Арил- и гетероарилзамещенные гетероциклические производные мочевины, способ лечения заболевания, опосредованного киназой raf, фармацевтическая композиция
RU2353616C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
JP2001526222A5 (cg-RX-API-DMAC7.html)
BR0010366A (pt) Composto, composição farmacêutica, método de preparar um composto, e, composto para uso em terapia
KR920009796A (ko) 3-아미도인돌릴 유도체
JP2003518060A5 (cg-RX-API-DMAC7.html)
CA2290744A1 (en) Cyclic diamine compounds and medicine containing the same
KR940005566A (ko) 퀴놀린 화합물
JP2005534669A5 (cg-RX-API-DMAC7.html)
CA2315713A1 (en) Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
DE69110320D1 (de) Stickstoff enthaltende heterozyklische Verbindungen, ihre Herstellung und Verwendung.
JP2005535586A5 (cg-RX-API-DMAC7.html)
CA2373653A1 (en) New use of compounds as antibacterial agents
ATE79376T1 (de) Dithioacetal-verbindungen, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE139233T1 (de) Annelierte thiophen-derivate, ihre herstellung und verwendung
RU99101081A (ru) Режим введения ингибиторов н+, к+-атфазы
JP2023522177A5 (cg-RX-API-DMAC7.html)
JP2004517843A5 (cg-RX-API-DMAC7.html)
JP2006501201A5 (cg-RX-API-DMAC7.html)
EP0397040A3 (en) N-heteroaryl-4-quinolinamines, a process for their preparation and their use as medicaments
JP2003513066A5 (cg-RX-API-DMAC7.html)
CA2382247A1 (en) Azaindoles having serotonin receptor affinity
JP2006528667A5 (cg-RX-API-DMAC7.html)
JP2005526773A5 (cg-RX-API-DMAC7.html)
RU2004122427A (ru) Пирролидин-2-оны в качестве ингибиторов фактора ха